The Good, Bad, and Dark of coffee. Coffee is uplifting and energizing. That cup of Joe for many is a morning ritual. There is research out that says coffee may be more of a mood enhancer than was once thought. Find out more>
Learn why a July 2010 article in the Archives of Internal Medicine questions the the wisdom of prescribing statin drugs for people with normal cholesterol levels, but who have other heart risk factors.
CellCept® (Mycophenalate Motefil) is an immunosuppressant drug which prevents a patient’s immune system from attacking organ transplants, including kidneys, livers, and hearts. The drug is manufactuered and sold by Swiss pharmaceutical company Hoffman-La Roche and has been available in the U.S. since 1995.
A recent study, published in the Archives of Internal Medicine, found that the cholesterol-lowering drugs known as statins increase the risk of diabetes within postmenopausal women by 48 percent.This new finding adds to a growing body of clinical evidence that statin drugs are fundamentally diabetogenic, which is not surprising considering the National Library of Medicine contains peer-reviewed, published research on over 300 other known adverse effects associated with their use.
LAST month, the Archives of Internal Medicine published a scathing reassessment of a 12-year-old research study of Neurontin, a seizure drug made by Pfizer. The study, which had included more than 2,700 subjects and was carried out by Parke-Davis (now part of Pfizer), was notable for how poorly it was conducted. The investigators were inexperienced and untrained, and the design of the study was so flawed it generated few if any useful conclusions. Even more alarming, 11 patients in the study…